IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.

In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.

Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.

Stephen Seliger, MD, and Michel Chonchol, MD, join Kidney Compass to discuss a pilot trial of empagliflozin in rapidly progressing ADPKD.

In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.

In this segment of her interview, Kimball discusses phase 2b tulisokibart data in hidradenitis suppurativa and the rationale for targeting TL1A.

Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.

Michael Wechsler, MD, discusses SWIFT/AGILE data showing 59% of patients in remission with depemokimab at year 1 maintained it at year 2.